William Aird/X
Sep 17, 2025, 10:54
Mitapivat Boosts ATP in Red Cells: Dr. William Aird on New Hope for Hemolytic Disorder
William Aird, Professor of Medicine at Harvard Medical School, posted on X:
”POWERING UP RBCs
Mitapivat is an oral allosteric activator of pyruvate kinase → ↑ glycolytic ATP.
FDA-approved for PK deficiency anemia; in trials for sickle cell disease and thalassemia.
More ATP = healthier, longer-lived red cells across hemolytic disorders.”
Stay updated with Hemostasis Today.
-
May 19, 2026, 11:15Sarah-Anne Nicholas: Excited to Share My First-Author Publication from My PhD Research
-
May 19, 2026, 10:45Jonathan Douxfils: Why Measuring NETosis Remains a Major Challenge in Translational Research
-
May 19, 2026, 10:39Maria Berghs: Rising Demand for Blood Donations in Sickle Cell Care
-
May 19, 2026, 10:27Amer Zeidan: Looking Forward to Sharing New AML Data at ESH 2026
-
May 19, 2026, 09:38Heghine Khachatryan: Why DVT in Elderly Patients Requires Special Attention?
-
May 19, 2026, 08:52Konstantin Stark: Announcing the Launch of Collaborative Research Center 1784 to Advance Thromboinflammation Research
-
May 19, 2026, 08:35Gokhan Ozdemir: Managing Acute Flow Diverter Stent Thrombosis in a Critical Vertebrobasilar Circulation
-
May 19, 2026, 08:28Rashad Falah: Evaluating Long Term Outcomes and Transfusion Risks in Obscure Gastrointestinal Bleeding
-
May 18, 2026, 16:35Abdurrahmaan Ali Suei Elbuzidi: What is the Optimal Anticoagulation Monitoring Target in ECMO?